BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2025 8:37:54 AM | Browse: 266 | Download: 366
 |
Received |
|
2025-03-07 10:07 |
|
Peer-Review Started |
|
2025-03-07 10:08 |
|
First Decision by Editorial Office Director |
|
2025-04-02 10:53 |
|
Return for Revision |
|
2025-04-02 10:53 |
|
Revised |
|
2025-04-09 14:26 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-04-18 02:42 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-04-18 06:45 |
|
Articles in Press |
|
2025-04-18 06:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-09-02 06:26 |
|
Publish the Manuscript Online |
|
2025-09-15 08:37 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Postoperative immune checkpoint inhibitors plus anti-angiogenesis for hepatitis B virus-associated hepatocellular carcinoma: Analyzing the evidence and future prospects
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Arunkumar Krishnan and Diptasree Mukherjee |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Arunkumar Krishnan, MD, Department of Supportive Oncology, Atrium Health Levine Cancer, 1021 Morehead Medical Drive, Charlotte, NC 28204, United States. dr.arunkumar.krishnan@gmail.com |
| Key Words |
Adverse events; Biomarkers; Bias; Confounders; Hepatitis B virus; Hepatocellular carcinoma; Postoperative combined therapy; Immunotherapy; Follow-up |
| Core Tip |
A recent study by Lu et al examined postoperative combined therapy (PCT) for hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC). While the findings provide important insights, it is essential to acknowledge several significant limitations. These include the potential for selection bias, a small sample size, and an insufficient focus on monitoring hepatitis B virus reactivation in detail. Future research should prioritize prospective, randomized controlled trials and adopt biomarker-driven approaches to advance the knowledge of the efficacy and safety of PCT. Moreover, extending follow-up periods and fostering global collaboration could enhance treatment outcomes and more effective patient care strategies in managing HBV-HCC. |
| Publish Date |
2025-09-15 08:37 |
| Citation |
Krishnan A, Mukherjee D. Postoperative immune checkpoint inhibitors plus anti-angiogenesis for hepatitis B virus-associated hepatocellular carcinoma: Analyzing the evidence and future prospects. World J Gastrointest Oncol 2025; 17(9): 106801 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i9/106801.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i9.106801 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
